Research of diagnosis and application of Aptamer in hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-655X.2019.02.015

Abstract

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common malignancies in digestive system and the second leading cause of cancer-related death. It has complicated pathogenesis, limited clinical treatments and poor prognosis. The screening and establishment of Aptamers can be used for molecular biological cell detection, image analysis and targeted therapy so as to be a new hope for the diagnosis and treatment of hepatocellular carcinoma. Relevant studies have made a good start from the detection of hepatocellular carcinoma cells and molecular markers, providing a new direction for the further progression of interfering signal pathways, mediating genes and targeted therapy.This review concentrates on the clinical diagnosis of hepatocellular carcinoma, the principle of Aptamer experiment and its progress in the diagnosis of hepatocellular carcinoma.

Key words: Carcinoma, hepatocellular, Systematic evolution of ligands by exponential enrichment, Aptamer, Tumor markes, biological

Yifei Chen, Wei Xia, Chen Gu, Shengmei Yang. Research of diagnosis and application of Aptamer in hepatocellular carcinoma[J]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(02): 141-144.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2019.02.015

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2019/V07/I02/141

Figures/Tables 1

References 26

[1]	Chen W, Zheng R, Baade PD，et al.Cancer statistics in China，2015 [J]．CA Cancer J Clin，2016，66(2):115-132.
[2]	Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma[J]．Nat Rev Dis Primers，2016(2):16018.
[3]	Schmidt S, Follmann M, Malek N，et al.Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma [J]．J Gastroenterol Hepatol，2011，26(12):1779-1786.
[4]	Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]．Nat Genet，2015，47(5):505-511.
[5]	European association for the study of the liver, european organisation for research and treatment of cancer.EASL-EORTC clinical practice guidelines：management of hepatocellular carcinoma [J]．J Hepatol，2012，56(4):908-943.
[6]	Verslype C, Rosmorduc O, Rougier P，et al.Hepatocellular carcinoma：ESMO-ESDO clinical practice guidelines for diagnosis，treatment and follow-up [J]．Ann Oncol，2012，23(Suppl7):41-48.
[7]	黄天从，李新丰，刘德鑫，等．甲胎蛋白异质体在老年肝癌诊断与肝动脉化疗栓塞治疗中的临床意义[J/CD]．中华诊断学电子杂志，2017，5(4):243-24
[8]	周文瑞，李新丰，林奇忆，等．血清甲胎蛋白异质体、高尔基体糖蛋白-73及甲胎蛋白检测在老年人原发性肝癌的诊断价值[J/CD]．中华诊断学电子杂志，2016，4(4):222-225.
[9]	Yu SJ.A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world：2010-2016 [J]．Clin Mol Hepatol，2016，22(1):7-17.
[10]	Marrero JA, Feng Z, Wang Y，et al.Alpha-fetoprotein，des-gamma carboxyprothrombin，and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma [J]．Gastroenterology，2009，137(1):110-118.
[11]	Yu B, Yang X, Xu Y，et al.Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas [J]．J Hepatol，2009，50(5):948-957.
[12]	Shen Q, Fan J, Yang XR，et al.Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma：a large-scale，multicentre study [J]．Lancet Oncol，2012，13(8):817-826.
[13]	Lin XJ, Chong Y, Guo ZW，et al.A serum microRNA classifier for early detection of hepatocellular carcinoma：a multicentre，retrospective，longitudinal biomarker identification study with a nested case-control study [J]．Lancet Oncol，2015，16(7):804-815.
[14]	Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy [J]．Cancer Discov，2016，6(5):479-491.
[15]	Zhou J, Huang A, Yang XR.Liquid biopsy and its potential for management of hepatocellular carcinoma [J]．J Gastrointest Cancer，2016，47(2):157-167.
[16]	Sun YF, Xu Y, Yang XR，et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection [J]．Hepatology，2013，57(4):1458-1468.
[17]	Huang A, Zhang X, Zhou SL，et al.Plasma circulating cellfree DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma [J]．J Cancer，2016，7(13):1798-1803.
[18]	Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment：RNA ligands to bacteriophage T4 DNA polymerase[J]．Science，1990，249(4968):505-510.
[19]	Ellington AD, Szostak JW.In vitro selection of RNA molecules that bind specific ligands[J]．Nature，1990，346(6287):818-822.
[20]	Ahmadyousefi Y, Malih S, Mirzaee Y，et al.Nucleic acid Aptamers in diagnosis of colorectal cancer[J]．Biochimie，2019(156):1-11.
[21]	Lu B, Wang J, Zhang J，et al.Screening and verification of ssDNA Aptamers targeting human hepatocellular carcinoma[J]．Acta Biochim Biophys Sin (Shanghai)，2014，46(2):128-135.
[22]	Chen H, Yuan CH, Yang YF，et al.Subtractive Cell-SELEX selection of DNA Aptamers binding specifically and selectively to hepatocellular carcinoma cells with high metastatic potential[J]．Biomed Res Int，2016 (2016):5735869.
[23]	Wang FB, Rong Y, Fang M, et al. Recognition and capture of metastatic hepatocellular carcinoma cells using Aptamer-conjugated quantum dots and magnetic particles[J]．Biomaterials，2013，34(15):3816-3827.
[24]	Du J, Hong J, Xu C，et al.Screening and Identification of ssDNA Aptamer for Human GP73[J]．Biomed Res Int，2015 (2015):610281.
[25]	Dong L, Tan Q, Ye W, et al. Screening and identifying a novel ssDNA Aptamer against alpha-fetoprotein using CE-SELEX[J]．Sci Rep，2015(5):15552.
[26]	Lee KA, Ahn JY, Lee SH，et al.Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in hepatocellular carcinoma (HCC)[J]．Sci Rep，2015(5):10897.

Please choose a citation manager

Content to export